Published in Cancer Res on June 15, 2001
Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1 | NCT00106158
Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun (2008) 1.45
Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One (2011) 1.29
Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors. Cancer Immun (2007) 0.99
A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun (2010) 0.97
Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget (2013) 0.94
Effects of CT-Xp gene knock down in melanoma cell lines. Oncotarget (2013) 0.93
Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res (2013) 0.90
Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer (2012) 0.86
Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.86
Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res (2015) 0.82
Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer. Exp Ther Med (2014) 0.80
HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer. Br J Cancer (2014) 0.79
MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases. J Immunother (2016) 0.78
Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma. Int J Clin Exp Pathol (2014) 0.77
Expression profile of SPACA5/Spaca5 in spermatogenesis and transitional cell carcinoma of the bladder. Oncol Lett (2016) 0.75
Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma. J Immunol Res (2015) 0.75
Effect of cancer/testis antigen NY-SAR-35 on the proliferation, migration and invasion of cancer cells. Oncol Lett (2016) 0.75
Melanoma: tumor microenvironment and new treatments. An Bras Dermatol (2017) 0.75
Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. Virchows Arch (2013) 0.75
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol (2017) 0.75
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature (1997) 14.91
A new class of murine leukemia virus associated with development of spontaneous lymphomas. Proc Natl Acad Sci U S A (1977) 13.96
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Tumor necrosis factor (TNF). Science (1985) 8.80
Ly-A and Ly-B: two systems of lymphocyte isoantigens in the mouse. Proc R Soc Lond B Biol Sci (1968) 7.51
Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J Exp Med (1975) 7.20
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A (1979) 6.93
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses. J Exp Med (1966) 6.45
The G (Gross) leukemia antigen. Cancer Res (1965) 6.07
The G-IX system. A cell surface allo-antigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. J Exp Med (1971) 6.06
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res (1999) 5.41
Surface alloantigens of plasma cells. J Exp Med (1970) 5.19
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Mechanisms of epithelial cell-cell adhesion and cell compaction revealed by high-resolution tracking of E-cadherin-green fluorescent protein. J Cell Biol (1998) 5.03
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 4.66
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med (1968) 4.63
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A (1976) 4.52
Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. Proc Natl Acad Sci U S A (1979) 4.14
Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A (1997) 4.10
Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci U S A (1978) 3.99
Improved complementation in the cytotoxic test. Transplantation (1970) 3.93
Current enigmas in cancer research. Harvey Lect (1973) 3.91
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
Inter-mitochondrial complementation: Mitochondria-specific system preventing mice from expression of disease phenotypes by mutant mtDNA. Nat Med (2001) 3.81
Wheat germ agglutinin. Molecular characteristics and specificity for sugar binding. J Biol Chem (1974) 3.80
G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology (1992) 3.79
p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci U S A (1981) 3.72
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med (2001) 3.60
Glycogen storage disease in adults. Ann Intern Med (1994) 3.58
Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. Proc Natl Acad Sci U S A (1982) 3.58
Antigenic structure of cell surfaces. An immunoferritin study of the occurrence and topography of H-2' theta, and TL alloantigens on mouse cells. J Exp Med (1969) 3.53
Immunoglobulin and other surface antigens of cells of the immune system. J Exp Med (1971) 3.50
An approach to the mapping of antigens on the cell surface. Proc Natl Acad Sci U S A (1968) 3.46
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Antigens of tumors and leukemias induced by viruses. Fed Proc (1966) 3.43
Ly-C: a third locus specifying alloantigens expressed only on thymocytes and lymphocytes. Transplantation (1971) 3.42
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics. J Exp Med (1977) 3.42
Genetic linkage relationships of loci specifying differentiation alloantigens in the mouse. Transplantation (1972) 3.34
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody. Proc Natl Acad Sci U S A (1967) 3.26
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Isolation and some characteristics of a group-specific antigen of the murine leukemia viruses. Virology (1969) 3.21
New paths in human cancer serology. J Exp Med (1998) 3.12
Relation of GIX antigen of thymocytes to envelope glycoprotein of murine leukemia virus. J Exp Med (1975) 3.06
Specific stimulation of actin gene transcription by epidermal growth factor and cycloheximide. Proc Natl Acad Sci U S A (1984) 3.00
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr (2006) 2.97
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer (2001) 2.95
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A (1990) 2.91
Assessment of prediction accuracy of protein function from protein--protein interaction data. Yeast (2001) 2.90
Mouse isoantigens: separation of soluble TL (thymus-leukemia) antigen from soluble H-2 histocompatibility antigen by column chromatography. J Exp Med (1967) 2.86
Shared viral antigen of mammalian leukaemia viruses. Nature (1970) 2.84
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
G (Gross) and H-2 cell-surface antigens: location on Gross leukemia cells by electron microscopy with visually labeled antibody. Proc Natl Acad Sci U S A (1970) 2.77
GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med (1982) 2.74
Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J (2000) 2.71
Immunogenetics of cell surface antigens of mouse leukemia. Annu Rev Genet (1977) 2.69
Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat Immunol (2000) 2.66
Use of hybrid antibody with anti-gamma-G and anti-ferritin specificities in locating cell surface antigens by electron microscopy. J Exp Med (1968) 2.62
Simple and reliable multiplex PCR assay for surveillance isolates of vancomycin-resistant enterococci. J Clin Microbiol (2000) 2.62